Volume 23, Issue 5 (Iranian South Medical Journal 2020)
Iran South Med J 2020, 23(5): 455-464 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Morovati-Sharifabad M, Yahyaie M, Salehi E. Prothrombin Time, an Indicator for Psoriasis Activity: A Case - Control Study. Iran South Med J 2020; 23 (5) :455-464
URL: http://ismj.bpums.ac.ir/article-1-1351-en.html
URL: http://ismj.bpums.ac.ir/article-1-1351-en.html
1- Department of Basic Sciences, School of Veterinary, Ardakan University, Ardakan, Iran , mmorovati@ardakan.ac.ir
2- Department of Basic Sciences, School of Veterinary, Ardakan University, Ardakan, Iran
2- Department of Basic Sciences, School of Veterinary, Ardakan University, Ardakan, Iran
Abstract: (2183 Views)
Background: Psoriasis is a common chronic and recurrent inflammatory skin disorder related to the
immune system and characterized by the rapid growth of skin cells. To date, no study has been
conducted on the role of the prothrombin time index in determining the disease activity and the prognosis of these patients. Recognizing the factors influencing the prognosis of this disease can be helpful. The aim of this study was to investigate the plasma levels of prothrombin time measured in patients with psoriasis, its association with the severity of the disease and its comparison with those of healthy people.
Materials and Methods: In this case-control study, we evaluated 20 age- and sex-matched patients with psoriasis and compared them with healthy people. A PASI criterion was used to measure the severity of the disease. In both groups, prothrombin time were assayed using a standard kit.
Results: The results showed prothrombin time in the patients and healthy people were 12.213±0.638 and 12.313±0.423 seconds, respectively. The two groups were not significantly different in terms of prothrombin time. (P=0.562).
Conclusion: This study revealed that prothrombin time were not affected by severity of the disease.
prothrombin time were not significant In the two groups, and cannot serve as a biological marker for
psoriasis activity.Further studies are needed to identify prognostic factors for psoriasis.
immune system and characterized by the rapid growth of skin cells. To date, no study has been
conducted on the role of the prothrombin time index in determining the disease activity and the prognosis of these patients. Recognizing the factors influencing the prognosis of this disease can be helpful. The aim of this study was to investigate the plasma levels of prothrombin time measured in patients with psoriasis, its association with the severity of the disease and its comparison with those of healthy people.
Materials and Methods: In this case-control study, we evaluated 20 age- and sex-matched patients with psoriasis and compared them with healthy people. A PASI criterion was used to measure the severity of the disease. In both groups, prothrombin time were assayed using a standard kit.
Results: The results showed prothrombin time in the patients and healthy people were 12.213±0.638 and 12.313±0.423 seconds, respectively. The two groups were not significantly different in terms of prothrombin time. (P=0.562).
Conclusion: This study revealed that prothrombin time were not affected by severity of the disease.
prothrombin time were not significant In the two groups, and cannot serve as a biological marker for
psoriasis activity.Further studies are needed to identify prognostic factors for psoriasis.
Type of Study: Original |
Subject:
General
Received: 2019/10/28 | Accepted: 2020/07/7 | Published: 2020/11/7
Received: 2019/10/28 | Accepted: 2020/07/7 | Published: 2020/11/7
References
1. Takeshita J, Grewal S, Langan SM, et al. Psoriasis And Comorbid Diseases: Epidemiology. J Am Acad Dermatol 2017; 76(3): 377-90. [DOI:10.1016/j.jaad.2016.07.064]
2. Kaffenberger BH, Lee GL, Tyler K, et al. Current And Potential Immune Therapies And Vaccines In The Management Of Psoriasis. Hum Vaccin Immunother 2014; 10(4): 876-86. [DOI:10.4161/hv.27532]
3. Osmani F, Hajizadeh E, Mansoori P. Estimation Of Seasonal Effect On The Psoriasis Recurrence Using Time Dependent Coefficient Rates Model For Recurrent Events. J Dermatol Cosmet 2015; 6(1): 23-30. (Persian)
4. Ansar A, Emami Z. Evaluation Of Serum Prolactin Level In Patients With Psoriasis. Avicenna J Clin Med 2015; 22(1): 43-7. (Persian)
5. Hou R, Yan H, Niu X, et al. Gene Expression Profile Of Dermal Mesenchymal Stem Cells From Patients With Psoriasis. J Eur Acad Dermatol Venereol 2014; 28(12): 1782-91. [DOI:10.1111/jdv.12420]
6. Burke CW. Vitamin K Deficiency Bleeding: Overview And Considerations. J Pediatr Health Care 2013; 27(3): 215-21. [DOI:10.1016/j.pedhc.2012.09.010]
7. Elyaspour Z, Akbarzadeh S, Iranpour D, et al. Relationship Of Serum Levels Of Vitamin K2 And Osteocalcin With Atherosclerotic Coronary Arteries. Iran South Med J 2018; 21(5): 353-61. (Persian)
8. Andras A, Tenna AS, Stewart M. Vitamin K Antagonists Versus Low‐Molecular‐Weight Heparin For The Long Term Treatment Of Symptomatic Venous Thromboembolism. Cochrane Database Syst Rev 2017; 7(7): CD002001. [DOI:10.1002/14651858.CD002001.pub3]
9. Beulens JW, Booth SL, Van Den Heuvel EG, et al. The Role Of Menaquinones (Vitamin K 2) In Human Health. Br J Nutr 2013; 110(8): 1357-68. [DOI:10.1017/S0007114513001013]
10. Quick AJ. The Nature Of The Bleeding In Jaundice. J Am Med Assoc 1938; 110(20): 1658-62. [DOI:10.1001/jama.1938.02790200026009]
11. Yang R, Moosavi L. Prothrombin Time. StatPearls [Internet]: Statpearls Publishing, 2019.
12. Garmo C, Bajwa T, Burns B. Physiology, Clotting Mechanism. Statpearls [Internet]: Statpearls Publishing, 2019.
13. Golafshan H, Ranjbaran R. Verification Of ISI In Local Laboratory. Lab Diagn 2015; 6(26): 26-9. (Persian)
14. Favaloro EJ. Optimizing The Verification Of Mean Normal Prothrombin Time (MNPT) And International Sensitivity Index (ISI) For Accurate Conversion Of Prothrombin Time (PT) To International Normalized Ratio (INR). New York: Humana Press - Hemostasis And Thrombosis, 2017, 59-74. [DOI:10.1007/978-1-4939-7196-1_4]
15. Crivello NA, Casseus SL, Peterson JW, et al. Age- And Brain Region-Specific Effects Of Dietary Vitamin K On Myelin Sulfatides. J Nutr Biochem 2010; 21(11): 1083-8. [DOI:10.1016/j.jnutbio.2009.09.005]
16. Kamata M, Tada Y. Safety Of Biologics In Psoriasis. J Dermatol 2018; 45(3): 279-86. [DOI:10.1111/1346-8138.14096]
17. Fredriksson T, Pettersson U. Severe Psoriasis- Oral Therapy With A New Retinoid. Dermatologica 1978; 157(4): 238-44. [DOI:10.1159/000250839]
18. Pabst M, Bondili JS, Stadlmann J, et al. Mass+ Retention Time= Structure: A Strategy For The Analysis Of N-Glycans By Carbon LC-ESI-MS And Its Application To Fibrin N-Glycans. Anal Chem 2007; 79(13): 5051-7. [DOI:10.1021/ac070363i]
19. Branisteanu DE, Voicu CM, Cretu A, et al. Adverse Reactions Of Biological Therapy For Psoriasis. Rev Med Chir Soc Med Nat Iasi 2015; 119(1): 38-44.
20. Bovenschen HJ, Van De Kerkhof PC, Van Erp PE, et al. Foxp3+Regulatory T Cells Of Psoriasis Patients Easily Differentiate Into IL-17A-Producing Cells And Are Found In Lesional Skin. J Invest Dermatol 2011; 131(9): 1853-60. [DOI:10.1038/jid.2011.139]
21. Furie B, Bouchard BA, Furie BC. Vitamin KDependent Biosynthesis Of Γ-Carboxyglutamic Acid. Blood 1999; 93(6): 1798-808. [DOI:10.1182/blood.V93.6.1798.406k22_1798_1808]
22. Ferland G. Vitamin K, An Emerging Nutrient In Brain Function. Biofactors 2012; 38(2): 151-7. [DOI:10.1002/biof.1004]
23. Higashi Y, Kanekura T, Kanzaki T. Enhanced Expression Of Cyclooxygenase (COX)‐2 In Human Skin Epidermal Cancer Cells: Evidence For Growth Suppression By Inhibiting COX‐2 Expression. Int J Cancer 2000; 86(5): 667-71.
https://doi.org/10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.0.CO;2-Y [DOI:10.1002/(SICI)1097-0215(20000601)86:53.0.CO;2-Y]
24. Hemmati A, Hooshmand GH, Ghorbanzadeh B, et al. Investigation Of The Local Healing Effects Of Vitamin K On Complete Skin Lesions In Albino Mice. Iranian Congress Of Physiology And Pharmacology. 2015 Sep. 7- 11, Kashan, Iran.
25. Nasiri S, Sedigha A, Moravej Farshi H, et al. Relationship Of Blood Levels Of Vitamins A And E With Psoriasis. Iran J Dermatol 2007; 10(2): 130-4.
26. Booth SL, Golly I, Sacheck JM, et al. Effect Of Vitamin E Supplementation On Vitamin K Status In Adults With Normal Coagulation Status. Am J Clin Nutr 2004; 80(1): 143-8. [DOI:10.1093/ajcn/80.1.143]
27. Ray D, Deshmukh P, Goswami K, et al. Antioxidant Vitamin Levels In Sickle Cell Disorders. Natl Med J India 2007; 20(1): 11-3.
28. Leveque N, Robin S, Muret P, et al. In Vivo Assessment Of Iron And Ascorbic Acid In Psoriatic Dermis. Acta Derm Venereol 2004; 84(1): 2-5. [DOI:10.1080/00015550310014717]
29. Khoshvaghti A, Nazifi S, Kazemi M. Simultaneous Effect Of Vitamin C And Warfarin On Coagulation Pathways Of Rats. J Shahid Sadoughi Univ Med Sci 2009; 17(4): 255-61. (Persian)
30. Menon GK, Elias PM. Ultrastructural Localization Of Calcium In Psoriatic And Normal Human Epidermis. Arch Dermatol 1991; 127(1): 57-63. [DOI:10.1001/archderm.1991.01680010067010]
31. Goldsmith LA, Katz SI, Gilchrest BA, et al. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: Mc Graw-Hill, 2012, 197-9.
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
